Andrea Silber, MD
Professor of Medicine (Medical Oncology)
Research & Publications
Biography
News
Coauthors
Selected Publications
- Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis StudySanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.
- Trends in breast cancer death by stage at diagnoses in 2000-2018.Kahn A, Marczyk M, Silber A, Rozenblit M, Sanft T, DiGiovanna M, Schellhorn S, Krop I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. DOI: 10.1200/jco.2023.41.16_suppl.e18855.
- Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer.Westvold S, KC M, Fan J, Hyslop T, Spees L, Wang S, Silber A, Oeffinger K, Dinan M. Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer. Journal Of Clinical Oncology 2023, 41: e24105-e24105. DOI: 10.1200/jco.2023.41.16_suppl.e24105.
- Abstract PD12-08: PD12-08 Randomized trial of exercise and nutrition on pathological complete response among women with breast cancer receiving neoadjuvant chemotherapy: the Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) StudyFerrucci L, Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Ligibel J, Irwin M. Abstract PD12-08: PD12-08 Randomized trial of exercise and nutrition on pathological complete response among women with breast cancer receiving neoadjuvant chemotherapy: the Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) Study. Cancer Research 2023, 83: pd12-08-pd12-08. DOI: 10.1158/1538-7445.sabcs22-pd12-08.
- Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207Chavez M, Miao J, Pusztai L, Goetz M, Rastogi P, Ganz P, Mamounas E, Paik S, Bandos H, Razaq W, O’Dea A, Kaklamani V, Silber A, Flaum L, Andreopolu E, Baar J, Wendt A, Carney J, Sharma P, Gralow J, Lew D, Barlow W, Hortobagyi G. Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207. Cancer Research 2023, 83: gs1-07-gs1-07. DOI: 10.1158/1538-7445.sabcs22-gs1-07.
- Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBCBlenman K, Marczyk M, Foldi J, Gunasekharan V, Silber A, Pusztai L. Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC. Cancer Research 2023, 83: p1-04-12-p1-04-12. DOI: 10.1158/1538-7445.sabcs22-p1-04-12.
- Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1)Belzer A, Silber A, Mehra S, Gilani S, Leventhal JS. Mucosal haemangioma in the setting of treatment with trastuzumab emtansine (T‐DM1). British Journal Of Dermatology 2022, 187: e168-e168. PMID: 35633104, DOI: 10.1111/bjd.21654.
- Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.
- Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
- Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
- A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer 2021, 22: 269-278. PMID: 34824002, DOI: 10.1016/j.clbc.2021.10.011.
- Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trialSanft T, Harrigan M, Cartmel B, Ferrucci LM, Li FY, McGowan C, Zupa M, Nguyen TH, Ligibel J, Neuhouser ML, Hershman DL, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Irwin ML. Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. Contemporary Clinical Trials 2021, 109: 106508. PMID: 34274495, PMCID: PMC10424280, DOI: 10.1016/j.cct.2021.106508.
- Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)Yardley D, Young R, Adelson K, Silber A, Kommor M, Najera J, Daniel D, Peacock N, Shastry M, Hainsworth J, Burris H. Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC). Cancer Research 2021, 81: ps11-29-ps11-29. DOI: 10.1158/1538-7445.sabcs20-ps11-29.
- Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
- Increasing accrual of minority patients in breast cancer clinical trialsTrant AA, Walz L, Allen W, DeJesus J, Hatzis C, Silber A. Increasing accrual of minority patients in breast cancer clinical trials. Breast Cancer Research And Treatment 2020, 184: 499-505. PMID: 32840699, DOI: 10.1007/s10549-020-05873-2.
- Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patientsYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D, Blenman K. Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients. Cancer Research 2020, 80: 4973-4973. DOI: 10.1158/1538-7445.am2020-4973.
- Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trialsTrant A, Walz L, Allen W, Verma H, Le M, DeJesus J, Hatzis C, Silber A. Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trials. Cancer Epidemiology Biomarkers & Prevention 2020, 29: a089-a089. DOI: 10.1158/1538-7755.disp18-a089.
- Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
- Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
- Abstract 2842: Vesal YaghoobiYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D. Abstract 2842: Vesal Yaghoobi. 2019, 2842-2842. DOI: 10.1158/1538-7445.sabcs18-2842.
- Abstract 2842: Vesal YaghoobiYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D. Abstract 2842: Vesal Yaghoobi. Cancer Research 2019, 79: 2842-2842. DOI: 10.1158/1538-7445.am2019-2842.
- A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.Sanft T, Harrigan M, Cartmel B, Ferrucci L, Basen-Engquist K, Hershman D, Ligibel J, Neuhouser M, Chagpar A, Jones B, Knobf M, Silber A, Li F, Irwin M. A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study. Journal Of Clinical Oncology 2019, 37: tps11633-tps11633. DOI: 10.1200/jco.2019.37.15_suppl.tps11633.
- Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).O'Meara T, Yaghoobi V, Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: e14180-e14180. DOI: 10.1200/jco.2019.37.15_suppl.e14180.
- Abstract PD6-02: Immunological differences between primary and metastatic breast cancerSzekely B, Bossuyt V, Li X, Baine M, Silber A, Sanft T, Hofstatter E, Mougalian S, Baghwagar S, Neumeister V, Pelekanou V, Hatzis C, Pusztai L. Abstract PD6-02: Immunological differences between primary and metastatic breast cancer. Cancer Research 2018, 78: pd6-02-pd6-02. DOI: 10.1158/1538-7445.sabcs17-pd6-02.
- Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
- Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
- Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races.Szekely B, Safonov A, Karn T, Bhagwagar S, Killelea B, Silber A, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. Journal Of Clinical Oncology 2017, 35: e13028-e13028. DOI: 10.1200/jco.2017.35.15_suppl.e13028.
- Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
- Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot studyEpstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study. Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
- Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysisYardley D, Peacock N, Young R, Silber A, Chung G, Webb C, Jones S, Shastry M, Midha R, DeBusk L, Hainsworth J, Burris H. Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis. Cancer Research 2016, 76: p5-14-04-p5-14-04. DOI: 10.1158/1538-7445.sabcs15-p5-14-04.
- Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.
- Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.
- Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.